
|Articles|March 1, 2003
Cannula approach using posterior delivery brings unparalleled safety
Posterior juxtascleral injection of he angiostatic steroid analog anecortave acetate (Alcon) has been associated with a remarkable safety profile in clinical trials evaluating it for the treatment of subfoveal choroidal neorvascularization (CNV) associated with age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
AAO 2025: Kenneth C. Fan, MD, sees vision gains with MCO-010 in Stargardt disease
3
AAO 2025: Understanding and diagnosing endophthalmitis
4
AAO 2025: Diana Do reviews the real-world use of aflibercept 8 mg
5